Association of Helicobacter pylori infection with the metabolic syndrome among HIV-infected black Africans receiving highly active antiretroviral therapy

Benjamin Longo-Mbenza, Teke Apalata, Murielle Longokolo, Marcel Mbula Mambimbi, Etienne Mokondjimobe, Thierry Gombet, Bertrand Ellenga, Baudouin Buassa-bu-Tsumbu, Guy Milongo Dipa, Evelyne Lukoki Luila, Augustin Nge Okwe

Abstract

Introduction: The metabolic syndrome (MetS) is common in human immune deficiency virus (HIV)-infected individuals receiving highly active antiretroviral therapy (HAART). Immune deficiencies caused by HIV give rise to numerous opportunistic gastrointestinal pathogens such as Helicobacter pylori, the commonest cause of chronic gastritis. The study sought to determine the relationship between H pylori infection and the MetS among HIV-infected clinic attendees.

Methods: This cross-sectional study was carried out in a specialised heart clinic in Kinshasa, DR Congo. Between January 2004 and December 2008, 116 HIV-infected patients (61 with MetS and 55 without MetS) who underwent upper gastrointestinal endoscopy for dyspeptic symptoms were included in the study following an informed consent. Univariate associations were determined by odds ratios (OR), while multivariate logistic regression analysis was used to identify factors associated with the MetS.

Results: H pylori infection (OR = 13.5, 95% CI: 10.3–17.6; \( p < 0.0001 \)) and peripheral obesity (median hip circumference ≥ 97 cm) (OR = 4.7, 95% CI: 1.2–18.8; \( p = 0.029 \)) were identified as MetS-related factors in HIV-infected patients. Higher rates of the MetS were associated with increased incidence of HIV-related immunocompromise using World Health Organisation (WHO) staging criteria. There was a univariate significant difference in the prevalence of the MetS between antiretroviral therapy (ART)-naïve patients and patients treated by means of a first-line HAART regimen of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP). However, this difference was not significant in multivariate logistic analysis.

Conclusion: H pylori infection was significantly associated with the MetS in HIV-infected patients.

Keywords: metabolic syndrome, Helicobacter pylori, HIV, HAART

Developing countries have recently been experiencing an increase in the prevalence of risk factors associated with the metabolic syndrome (MetS) and cardiovascular diseases (CVD) in both general and working class populations. Progressive urbanisation and westernisation of lifestyle leading to an epidemiological transition in developing countries can be mentioned among possible reasons. The metabolic syndrome is a cluster of metabolic and haemodynamic risk factors that act multiplicatively to promote atherosclerotic CVD and type 2 diabetes mellitus (T2DM). Its initial description by Reaven (1988) included dyslipidaemia, hypertension, hyperglycaemia and insulin resistance. These disturbances promote an elevated prothrombotic/procoagulant state, endothelial cell dysfunction and inflammatory response with premature atherosclerotic complications. Helicobacter pylori, a spiral-shaped gram-negative flagellated bacterium, enhances human chronic inflammatory diseases.
Epidemiological data from the literature support a significant association of *H pylori* seropositivity with CVD, insulin resistance and elevated parameters of the metabolic syndrome.12,13

The risk of the MetS is greater in HIV-infected individuals compared with the general population because of a greater prevalence of lipid and glucose abnormalities.14,15 HIV infection itself is associated with disturbances in lipid metabolism such as hyperglyceridaemia, and a decrease in total cholesterol and high-density lipoprotein (HDL) cholesterol levels.16 Treatment of HIV infection with highly active antiretroviral therapy (HAART) can also induce severe metabolic complications including lipodystrophy, dyslipidaemia, and insulin resistance. Patients with HIV infection and the MetS had increased intima–media thickness (IMT), similar to that found in diabetes.

While inflammation is recognised as a major contributor in the pathogenesis of both diabetes and atherosclerosis, little is known about the key inflammatory molecules involved in atheroma and diabetes in HIV-positive HAART recipients. However, epidemiological studies have shown that *H pylori* infection has become a common cause of chronic gastritis in HIV/AIDS patients.17 It is possible that prevalent infection by *H pylori* enhances the inflammatory process observed in the atheroma of HAART-recipient HIV-positive individuals, leading to CVD and the MetS.

In many central African countries, the first-line anti-retroviral therapy (ART) protocol in the public health sector recommends the combination of three drugs ( stavudine, lamivudine and efavirenz), commonly referred to as ‘regimen 1A’. In ‘regimen 1B’, efavirenz is substituted with nevirapine, particularly in previously diagnosed type 2 diabetes. Other participants met the criteria for high blood pressure or high fasting glucose levels if they were currently on antihypertensive or oral hypoglycaemic therapies, respectively.

The cardiometabolic co-morbidities included arterial hypertension, type 2 diabetes, myocardial infarction, stroke, long QTc ≥ 0.420 ms, gout/hyperuricaemia (uric acid ≥ 7 mg/dl), and subclinical atherosclerosis (pulse pressure ≥ 60 mmHg + IMT ≥ 1 mm or carotid plaque).12,13

### Definitions and criteria for the MetS

Criteria defined by the 2005 International Diabetes Federations (IDF) report were used to ascertain cases of the MetS.12 Participants with three of the following criteria were defined as having the metabolic syndrome: prerequisite was waist circumference ≥ 94 cm in men and ≥ 80 cm in women; triglycerides ≥ 150 mg/dl (1.7 mmol/l); HDL cholesterol < 40mg/dl (1.03 mmol/l) in men and < 50 mg/dl (1.29 mmol/l) in women; systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg; and fasting glucose ≥ 100 mg/dl (5.6 mmol/l) or previously diagnosed type 2 diabetes. Other participants met the criteria for high blood pressure or high fasting glucose levels if they were currently on antihypertensive or oral hypoglycaemic therapies, respectively.

### Laboratory investigations

The initial HIV test was performed using HIV rapid test (SmartCheck test, World Diagnostics Inc, USA) while a confirmatory test following an initial positive HIV result was performed using Uni-Gold™ Recombigen® HIV (Trinity Biotech PLC, USA) from the blood samples. CD4+ lymphocyte cell count was measured using CyFlowR Counter (Partec GmbH; Munstar, Germany) and HIV RNA viral load was quantified by means of Nuclisens Easy Q HIV-1 system (BioMérieux, Box tel, the Netherlands).

Haemoglobin and haematocrit levels were measured in blood using standard haematological techniques. Fasting glucose levels were measured from plasma samples using the glucose-oxidase method and spectrophotometer (Hospitex Diagnostics, Florence, Italy). Total cholesterol, HDL cholesterol, uric acid and triglyceride levels were measured using enzymatic colorimetric methods (BioMérieux, Marcy l’Etoile, France). Oxidised low-density lipoprotein (LDL) cholesterol, a biomarker of oxidative stress, was measured using solid-phase two-side enzyme immunoassay (Merckodia AB, Sylveniusgatan 8A, SE754 50, Uppsala, Sweden).
**Imaging techniques**

Subclinical atherosclerosis was assayed by IMT using echo-Doppler, and the diagnosis of *H. pylori*-related chronic gastritis was confirmed as described elsewhere. Atherosclerotic complications including different forms of CVD (myocardial infarction, stroke, peripheral artery disease) were ascertained by clinical symptoms and signs, cardiac enzymes and troponin levels, as well as results from electrocardiogram, echo-Doppler, tomodensitometry and coronary angiogram.

**Statistical analyses**

Data were expressed as means ± standard deviation (SD) for the continuous variables and proportions (percentages) for the categorical variables. The Student’s *t*-test was used to assess differences between two means and ANOVA between categorical variables. The Student’s *t*-test was performed to 

**Table 1. Univariate factors associated with the metabolic syndrome in HIV-infected individuals (n = 116)**

| Variable of interest | Presence of MetS | Absence of MetS | OR (95% CI) | p-value |
|----------------------|------------------|-----------------|-------------|---------|
| Gender               |                  |                 |             |         |
| males (n = 54)       | 31 (57.4)        | 23 (42.6)       |             | 1.4 (0.7 - 3) 0.332 |
| females (n = 62)     | 30 (48.4)        | 32 (51.6)       |             |         |
| Socio-economic status (SES) |              |                 |             | 3.3 (1.4 - 7.8) 0.004 |
| high (n = 36)        | 26 (72.2)        | 10 (27.8)       |             | <0.0001 |
| low (n = 80)         | 35 (43.8)        | 45 (56.2)       |             |         |
| Smoking              |                  |                 |             | 10.5 (2.9 - 37.9) <0.0001 |
| yes (n = 26)         | 23 (88.5)        | 3 (11.5)        |             |         |
| no (n = 90)          | 38 (42.2)        | 52 (57.8)       |             |         |
| *Helicobacter pylori* seropositivity |              |                 |             | 95.3 (20.4 - 444.7) <0.0001 |
| yes (n = 72)         | 59 (81.9)        | 13 (18.1)       |             |         |
| no (n = 44)          | 2 (4.5)          | 42 (95.5)       |             |         |
| *H. pylori* gastritis due to |              |                 |             | 28.1 (9.5 - 83) <0.0001 |
| yes (n = 50)         | 45 (90)          | 5 (10)          |             |         |
| no (n = 66)          | 16 (24.2)        | 50 (75.8)       |             |         |
| Peripheral obesity (median hip circumference ≥ 97 cm) |          |                 |             | 4.6 (2.1 - 10) <0.0001 |
| yes (n = 58)         | 41 (70.7)        | 17 (29.3)       |             |         |
| no (n = 58)          | 20 (32.8)        | 38 (67.2)       |             |         |
| Excessive alcohol intake |              |                 |             | 3.3 (1.5 - 7.4) 0.003 |
| yes (n = 44)         | 31 (70.5)        | 13 (29.5)       |             |         |
| no (n = 72)          | 30 (41.7)        | 42 (58.3)       |             |         |
| HAART exposure       |                  |                 |             | 2.4 (1.01 - 5.7) 0.045 |
| yes (n = 63)         | 34 (52.3)        | 31 (47.7)       |             |         |
| no (n = 35)          | 11 (31.4)        | 24 (68.6)       |             |         |

Variables were first computed to identify univariate potential factors and cardiometabolic co-morbidities associated with the MetS; the significant association between variables being calculated as odds ratios (OR) with 95% confidence interval (CI). Potential factors demonstrating a univariate relationship (*p* < 0.20) with the MetS were included in the multivariate logistic regression analysis to assess the effect of their independent association with the MetS. Goodness-of-fit was verified with the Hosmer and Lemeshow statistical method. A *p*-value < 0.05 was considered statistically significant. All data were analysed using the Statistical Package for the Social Sciences (SPSS for Windows, version 21; Chicago, IL).

**Results**

A total of 116 heterosexual HIV-infected patients were enrolled. Of the 116 eligible study participants, 54 (46.6%) were men and 62 (53.4%) women. The mean age of the study participants was 42 ± 9 years. Of these, 65 (56%) were ART naive and 51 (44%) were on a 13 ± 1 month first-line HAART regimen of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP). No patient received either efavirenz or protease inhibitors. Based on the 2005 International Diabetes Federation definition, 61/116 patients (52.6%) met the criteria for the MetS versus 55/116 patients (47.4%) without the MetS.

During univariate analyses, numerous factors were shown to be significantly associated with the MetS in HIV-infected individuals, as depicted in Tables 1 and 2. There was a significant univariate association in the prevalence of the MetS between ART-naive patients and those treated by means of a first-line HAART regimen of d4T, 3TC and NVP (Table 1) but this association did not reach significant difference in multivariate regression analysis.

**Table 2. Other univariate factors associated with metabolic syndrome in HIV-infected individuals (n = 116)**

| Variable of interest | Presence of MetS | Absence of MetS | p-value |
|----------------------|------------------|-----------------|---------|
| Age (years)          | 46.4 ± 8         | 40.8 ± 11.1     | 0.005   |
| BMI (kg/m²)          | 23.1 ± 4.4       | 20.5 ± 4.1      | 0.003   |
| WC (cm)              | 109.2 ± 16.8     | 90.6 ± 16.6     | <0.0001 |
| HC (cm)              | 111.6 ± 13.7     | 103.2 ± 16.3    | 0.013   |
| SBP (mmHg)           | 138.7 ± 25.1     | 114.5 ± 21      | 0.005   |
| DBP (mmHg)           | 77.1 ± 12.9      | 72.3 ± 12.2     | 0.068   |
| Pulse pressure (mmHg) | 61.6 ± 23.2     | 42.2 ± 13.2     | <0.0001 |
| Haemoglobin (g/dl)   | 13.7 ± 1.1       | 12.2 ± 1.8      | 0.005   |
| Haematocrit (%)      | 36.8 ± 5.9       | 28.2 ± 7.4      | <0.0001 |
| *H. pylori* infection | 93.0 ± 61.1     | 126.9 ± 192.1   | <0.0001 |
| CD4+ count (cells/mm³) | 190.5 ± 157.9  | 181.5 ± 193.9   | 0.02**  |
| Viral load (copies/ml) | 270.037 ± 147064 | 208741 ± 102629 | <0.0001** |
| Uric acid (mg/dl)    | 33.9 ± 10.2      | 10.7 ± 10.8     | <0.0001 |
| Fasting glucose (mg/dl) | 130.1 ± 26.4  | 106.4 ± 50.2    | 0.008   |
| HDL-C (mg/dl)        | 7.22 ± 1.47      | 5.91 ± 2.79     | 0.018   |
| Total cholesterol (mg/dl) | 193.9 ± 51.9  | 157.6 ± 79.8    | 0.018   |
| Triglycerides (mg/dl) | 208 ± 9.3       | 208 ± 9.3       | 0.001   |
| Oxidised LDL-C (mg/dl) | 155.1 ± 0.3    | 101.2 ± 0.1     | <0.0001  |

**Non-parametric Mann–Whitney U-test**
When using non-parametric Mann–Whitney U-tests, there were significant univariate associations of CD4+ T cell counts and HIV viral loads with the MetS (Table 2). There was also a significant relationship ($p < 0.0001$) between the WHO HIV disease stages and the presence of the MetS (Fig. 1).

HIV-infected patients of WHO stages 3 and 4 were in CDC stage C and those of WHO stages 1 and 2 were in CDC stage B.

However, during multivariate logistic regression analysis, after adjusting for age, SES, HAART exposure, smoking, excessive alcohol intake, plasma HIV loads, $H$ pylori seropositivity (constant $B = 5.2$; SE = 1.114;wald $\chi^2 = 21.785$; OR = 13.5; 95% CI: 10.3–17.6; $p < 0.0001$) and peripheral obesity (median hip circumference $\geq 97$ cm) (constant $B = 1.545$; SE = 0.708;wald $\chi^2 = 4.756$; OR = 4.7; 95% CI: 1.2–18.8; $p = 0.029$) were identified as the only factors significantly associated with the MetS in HIV-infected patients.

Discussion

The metabolic syndrome is recognised as a major public health concern, even in the absence of HIV infection.\(^6\)\(^,\)\(^7\)\(^,\)\(^8\)\(^,\)\(^9\) The majority of patients with the MetS were defined by high SES, physical inactivity, excessive alcohol intake, and total and peripheral obesity.\(^10\) In Africa, many individuals gain weight later in their adult life and do not want to lose weight because of the stigma of HIV.\(^11\) Furthermore, abdominal obesity is considered a social achievement.

Lifestyle has a strong influence on the MetS, particularly among HIV-infected patients. Therefore the main emphasis in the management of the MetS should focus on addressing lifestyle changes, mainly efforts to stop smoking, reduce body weight and alcohol intake, and increase moderate physical activity. Elevated blood pressure, dyslipidaemia and hyperglycaemia may however require additional drug treatment.

Additional correlates of the MetS among HIV-infected Africans in our study population were hypercoagulability, increased levels of uric acid, and infection/inflammatory markers, as reported in other study cohorts of both HIV-infected and uninfected patients.\(^4\)\(^,\)\(^2\)\(^,\)\(^3\) Helicobacter pylori infection and hip circumference $\geq 97$ cm (peripheral obesity) were identified as the only factors associated with the MetS in our study population during a multivariate analysis.

Findings from this study showed only univariate association between exposure to first-line combination antiretroviral therapy and the MetS. A previous report from the literature has underlined the independent role of stavudine (d4T as a part of ARV) in determining the MetS in HIV-infected populations.\(^12\) A possible contribution of the nucleoside analogue stavudine to lipid abnormalities was also previously reported in the literature.\(^13\)

Numerous other studies confirmed that non-nucleoside reverse transcriptase inhibitors had a more favourable impact on lipid levels than most members of the protease inhibitor class.\(^14\)\(^,\)\(^15\)\(^,\)\(^16\)

In addition, higher frequency of coronary heart disease,\(^17\) stroke\(^18\) and diabetes mellitus\(^19\) have been observed by others in HIV/AIDS patients with the MetS. Oxidative stress-mediated LDL cholesterol modification may be a key role player in initiation and exacerbation of the MetS and atherosclerosis in these HIV-infected patients.

Findings from this present study have supported the association between $H$ pylori infection and larger hip circumference ($\geq 97$ cm). Appropriate lifestyle changes and in some cases, medication (antibiotics, statins, antihypertensives, antidiabetic drugs) may improve all of the MetS components. Getting more physical activity, losing weight (5–10% of weight), quitting smoking, limiting alcohol intake and appropriate diet (vitamins, antioxidants, fruits, vegetables, fish and whole grains) could be proposed to patients with the MetS.

Limitations of this study are mainly the small size of the study sample, the cross-sectional study design, and absence of an HIV-negative group. In this regard, results reported herein are only associations from which no conclusions regarding causality can be drawn.

Conclusion

$H$ pylori infection and peripheral obesity (median hip circumference $\geq 97$ cm) were shown to be associated with higher risk of the MetS in HIV/AIDS patients. Screening for the presence of $H$ pylori infection can be helpful when managing HIV/AIDS patients diagnosed with the MetS. However, further studies are warranted in order to ascertain the value of this recommendation.

References

1. World Health Organisation (WHO). Cardiovascular Disease Prevention and Control, 2003. Accessed at http/www.who.int/cardiovascular-disease.
2. Longo-Mbenza B, Nkoy Belila J, Vangu Ngoma D, Mbungu S. Prevalence and risk factors of arterial hypertension among urban Africans in workplace: the obsolete role of body mass index. Niger J Med 2007; 16: 42–49.
3. Gombi T, Longo-Mbenza B, Ellenga-Mbolla B, Ikama MS, Kimbally-Kaky G, Nkoua JL. Relationship between coronary heart disease, metabolic syndrome, energy expenditure, body composition, kidney function and low-grade inflammation among bank African employees in Brazzaville. Diab Metab Syndr Clin Res Rev 2010; 4(4): 197–203.
4. Longo-Mbenza B, Nkondi Nsenga J, Vangu Ngoma D. Prevention of the metabolic syndrome insulin resistance and the atherosclerotic diseases in Africans infected by Helicobacter pylori infection and treated by antibiotics. Int J Cardiol 2007; 121: 229–238.
5. Longo-Mbenza B, Nge Okwe A, Kangola Kabangu N, Mbungu FS. Metabolic syndrome, aging, physical inactivity, and incidence of type 2 diabetes in general African population. Diab Vasc Dis Res 2010; 7(1):
28–39.

6. Grundy SM, Brewer B, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004; 109: 433–438.

7. Ford ES. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of evidence. Diabetes care 2005; 28: 1769–1778.

8. Reaven GM. Banting lecture 1998. Role of insulin resistance in human disease. Diabetes 1998; 37: 1595–1607.

9. Ridker PM, Buring JE, Rifai N. C-reactive protein, the meta-

dilestone syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003; 107: 391–397.

10. Chapman MJ. Metabolic syndrome and type 2 diabetes: lipid and physio-

logical consequences. Diabetes Vasc Dis Res 2007; 4(suppl): S5–S8.

11. Wang CM, Kaltenboeck B. Exacerbation of chronic inflammatory diseases by infectious agents: Fact or fiction? World J Diabetes 2010; 1: 27–35.

12. Aydemir S, Bayraktaroglu T, Mungan G, et al. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci 2005; 50: 2090–2093.

13. Lipid and Physiological Consequences. Diabetes Vasc Dis Res 2007; 4(suppl): S5–S8.

14. Aydemir S, Bayraktaroglu T, Sert M, Sokmen C, Atmaca H, Mungan G, et al. The effect of Helicobacter pylori on insulin resistance. Dig Dis Sci 2005; 50: 2090–2093.

15. Bonfanti P, Giannattasio C, Ricci E, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007; 45: 426–431.

16. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipo-

dystrophy, hyperlipidemia and insulin resistance due to HIV protease in-

hibitors. AIDS A998; 12: F51–58.

17. Huyghe MR, Orenstein JM. Opportunistic disorders of the gastrointesti-

tinal tract in the age of highly active antiretroviral therapy. Hul Pathol 2010; 41: 1777–1787.

18. Coats AJS, Shewan LG. Statement on authorship and publishing ethics in the International Journal of Cardiology. Int J Cardiol 2011; 153: 239–240.

19. World Health Organization: acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV-A infection and disease. Wkly Epidemiol Rec 1990; 65: 221–228.

20. Centers for disease control and prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41: 1–19.

21. Alberti KG, Zimmet P, Shaw J. IDF Epidemiology Task Force consensus group. The metabolic syndrome—a new worldwide definition. Lancet 2005; 366: 1059–1062.

22. Longo-Mbenza B, Bielle E, Muls E, Vangu N, Dita Mpadamadi S. The role of early hemodynamic impairment and disease duration on diabetic cardiomyopathy and hypertension in central Africans with atheroscle-

rosis. J Diabetes Complicat 2002, 16: 146–152.

23. Longo-Mbenza B, Kasiam Lasi On'kin JB, Nge Okwe A, Vangu Ngoma D, Mbungu Fuele S, Milongo Dipa G. Comparison of abdominal obesity and total obesity in predicting risk of prehypertension status with reference to economic development in the south-west of Congo. Circulation 2008; 117 [Abstract 0169].

24. Jaccobellis G, Sharma AM, Pellicelli AM, Grisorio B, Barbarini G, Barbaro G. Epicardial adipose tissue is related to carotid intima–media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. Curr HIV Res 2005; 7: 275–279.

25. Fezeu L, Balkau B, Kengne AP, Sobngwi E, Mbanya JC. Metabolic syndrome in a sub-Saharan African setting: Central obesity may be the key determinant. Atherosclerosis 2007; 193: 70–76.

26. Currier J. Management of metabolic complications of therapy. AIDS 2002; 16(suppl 4): S171–S176.

27. Staszewski S, Galian J, Posnak A, et al. Efficacy and safety of tenofovir disoproxil fumarate (TDF) versus stavudine (d4T) when used in combi-

nation with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected patients naive to antiretroviral therapy (ART): 48-week interim results. XIV International AIDS Conference. Barcelona, 2002.

28. Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003; 17(suppl 1): 141–148.

29. Longo-Mbenza B, Seghers KV, Phuati M, Bikangi FN, Mubagwa K. Heart involvement and HIV infection in African patients: determinants of survival. Int J Cardiol 1998; 64: 63–73.

30. Bau, MK, Rafie C, Lai S, et al. Coronary heart disease (CHD) risk factors and metabolic syndrome in HIV-positive drug users in Miami. Am J Infect Dis 2006; 2: 173–179.

31. Mcohan A, Modi M, Modi G. Stroke in black South African HIV-positive patients. A prospective analysis. Stroke 2003; 34: 10–15.

32. Samariansinghe YP, Higgs C, Gazzard B, Feher MD. Diabetes in a HIV population: a hidden epidemic. Diab Met 2002; 19(suppl 2): 28–115.